1 Department of Breast Surgery, Affiliated Hospital of Hebei University , Baoding, China .
2 Central Laboratory, Hebei Laboratory of Mechanism and Procedure of Cancer Radiotherapy and Chemotherapy, Affiliated Hospital of Hebei University , Baoding, China .
Cancer Biother Radiopharm. 2018 Jun;33(5):169-175. doi: 10.1089/cbr.2017.2327. Epub 2018 Jun 6.
Resistance to therapies and disease recurrences after surgery or treatment are common challenges in breast cancer management in clinic. Active immunotherapy using human epidermal growth factor receptor 2 (HER2)-targeted vaccines represents an attractive option in combating breast cancer. Different HER2-derived vaccines have been developed over the years. Many clinical trials have been carried out in evaluating HER2-based vaccines. The authors reviewed current literature on HER2-based vaccines in clinical trials. The trials covered in this mini-review represent some of the major trials published in the past 20 years regarding the clinical use and test of HER2 vaccines. Their focus is on trials using HER2 peptide vaccines as the majority of clinical trials initiated or published used HER2 peptide-based vaccines. Findings from combination therapy trials of HER2 peptide vaccines with other treatment modalities are also presented.
在临床乳腺癌管理中，治疗耐药和手术后疾病复发是常见的挑战。使用人表皮生长因子受体 2（HER2）靶向疫苗的主动免疫疗法是对抗乳腺癌的一种有吸引力的选择。多年来已经开发了不同的 HER2 衍生疫苗。许多临床试验已经在评估基于 HER2 的疫苗。作者回顾了临床试验中基于 HER2 的疫苗的当前文献。本综述中涵盖的试验代表了过去 20 年中关于 HER2 疫苗临床应用和检测的一些主要试验。它们的重点是使用 HER2 肽疫苗的试验，因为大多数启动或发表的临床试验都使用基于 HER2 肽的疫苗。还介绍了 HER2 肽疫苗与其他治疗方式联合治疗试验的结果。
